Prevention of Late-Onset Cytomegalovirus Infection and Disease in Donor-Positive/Recipient-Negative Kidney Transplant Recipients Using Low-Dose Valganciclovir

Our novel protocol prevented late-onset CMV infection and disease beyond 1 year post-transplantation in D+/R− recipients.